Importer of Controlled Substances; Notice of Registration; Meridian Medical Technologies, 31388-31389 [2012-12813]
Download as PDF
<![CDATA[
31388
Federal Register / Vol. 77, No. 102 / Friday, May 25, 2012 / Notices
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 25, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in Schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12828 Filed 5–24–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Noramco, Inc.
Pursuant to Title 21 Code of Federal
Regulations § 1301.34(a), this is notice
that on August 18, 2011, Noramco, Inc.,
500 Swedes Landing Road, Wilmington,
Delaware 19801–4417, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the following basic
classes of controlled substances:
Drug
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2012–12825 Filed 5–24–12; 8:45 am]
II
II
II
II
BILLING CODE P
Jkt 226001
The company plans to import the
listed controlled substance in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically manufactured FDF. This
analysis is required to allow the
company to export domestically
manufactured FDF to foreign markets.
In reference to the import of Fentanyl
(9801), the authorization for the import
of this basic class of controlled
substance is granted only for analytical
testing and clinical trials. This
authorization does not extend to the
import of a finished FDA approved or
non-approved dosage form for
commercial distribution in the United
States.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Capricorn Pharma, Inc., to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Capricorn Pharma, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12824 Filed 5–24–12; 8:45 am]
DEPARTMENT OF JUSTICE
The company plans to import the raw
Opium (9600) and Poppy Straw
Concentrate (9670) to manufacture other
controlled substances. The company
plans to import Tapentadol (9780) in
intermediate form for the bulk
manufacture of Tapentadol (9780)
which it will distribute to its customers.
The company plans to import the
Phenylacetone (8501) in bulk for the
manufacture of a controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
17:55 May 24, 2012
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
VerDate Mar<15>2010
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 25, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
BILLING CODE 4410–09–P
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Capricorn
Pharma, Inc.
By Notice dated March 8, 2012, and
published in the Federal Register on
March 20, 2012, 77 FR 16262, Capricorn
Pharma, Inc., 6900 English Muffin Way,
Unit A, Frederick, Maryland 21703,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Fentanyl
(9801), a basic class of controlled
substance listed in schedule II.
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Meridian
Medical Technologies
By Notice dated March 23, 2012, and
published in the Federal Register on
April 2, 2012, 77 FR 19716, Meridian
Medical Technologies, 2555 Hermelin
Drive, St. Louis, Missouri 63144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
E:\FR\FM\25MYN1.SGM
25MYN1
31389
Federal Register / Vol. 77, No. 102 / Friday, May 25, 2012 / Notices
be registered as an importer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world,
including Europe. The company has
been asked to ensure that its product
sold to European customers meets
standards established by the European
Pharmacopeia, which is administered
by the Directorate of the Quality of
Medicines (EDQM). In order to ensure
that its product will meet European
specifications, the company seeks to
import morphine supplied by EDQM to
use as reference standards. This is the
sole purpose for which the company
will be authorized by DEA to import
morphine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Meridian Medical Technologies to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Meridian Medical Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substances listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
Coca Leaves (9040) .....................
Raw Opium (9600) .......................
Poppy Straw (9650) .....................
Poppy Straw Concentrate (9670)
II
II
II
II
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
Comments and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007)
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a), and
determined that the registration of
Penick Corporation to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Penick Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12830 Filed 5–24–12; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2012–12813 Filed 5–24–12; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Penick
Corporation
By Notice dated April 17, 2012 and
published in the Federal Register on
April 26, 2012, 77 FR 24983, Penick
Corporation, 33 Industrial Park Road,
VerDate Mar<15>2010
17:55 May 24, 2012
Jkt 226001
Importer of Controlled Substances;
Notice of Registration; Cerilliant
Corporation
By Notice dated March 8, 2012, and
published in the Federal Register on
March 20, 2012, 77 FR 16261, Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, Texas 78665–2402, made
application by letter to the Drug
Enforcement Administration (DEA) to
PO 00000
Frm 00100
Fmt 4703
Sfmt 9990
be registered as an importer of the
following basic classes of controlled
substances:
Drug
4-methyl-N-methylcathinone
(1248).
1-Pentyl-3-(1-naphthoyl)indole
(7118).
1-Butyl-3-(1-naphthoyl)
indole
(7173).
1-[2-(4-Morpholinyl)-ethyl}-3-(1naphthoyl)indole (7200).
5-(1,1-Dimethylheptyl)-2-{(1R,3S)3-hydroxycyclohexyl]-phenol
(7297).
5-(1,1-Dimethyloctyl)-2[(1R,3S)-3hydroxycyclohexyl]
phenol
(7298).
3,4-methylenedioxypyrovalerone
(7535).
3,4-methylenedioxy-Nmethylcathinone (7540).
Desomorphine (9055) ...................
Schedule
I
I
I
I
I
I
I
I
I
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Cerilliant Corporation to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Cerilliant Corporation
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12826 Filed 5–24–12; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 77, Number 102 (Friday, May 25, 2012)]
[Notices]
[Pages 31388-31389]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12813]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration;
Meridian Medical Technologies
By Notice dated March 23, 2012, and published in the Federal
Register on April 2, 2012, 77 FR 19716, Meridian Medical Technologies,
2555 Hermelin Drive, St. Louis, Missouri 63144, made application by
renewal to the Drug Enforcement Administration (DEA) to
[[Page 31389]]
be registered as an importer of Morphine (9300), a basic class of
controlled substance listed in schedule II.
The company manufactures a product containing morphine in the
United States. The company exports this product to customers around the
world, including Europe. The company has been asked to ensure that its
product sold to European customers meets standards established by the
European Pharmacopeia, which is administered by the Directorate of the
Quality of Medicines (EDQM). In order to ensure that its product will
meet European specifications, the company seeks to import morphine
supplied by EDQM to use as reference standards. This is the sole
purpose for which the company will be authorized by DEA to import
morphine.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Meridian Medical Technologies to import the basic class
of controlled substance is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. DEA has investigated Meridian
Medical Technologies to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic class of controlled substances
listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12813 Filed 5-24-12; 8:45 am]
BILLING CODE 4410-09-P
